Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Marketing authorization applications submitted for Femara in U.S. and Europe
August 11th, 2005
Novartis has submitted marketing authorization applications in the United States and Europe for the use of Femara (letrozole tablets) in the adjuvant (post-surgery) treatment of postmenopausal women with hormone receptor-positive early breast cancer. Once approved for this indication, Femara will become the only breast cancer treatment available to significantly reduce the risk of recurrence in the adjuvant setting as well as in extended adjuvant treatment following tamoxifen. "Femara represents an important advance to help increase a woman's chance of staying cancer free after initial treatment for early breast cancer," said Diane Young, MD, vice...
Source: Women's Health Weekly (2005-08-11)
|
